Report Overview

2023

Base Year

2018-2023

Historical Year

2024-2032

Forecast Year

Global Adalimumab Drugs Market Regional Analysis

North America, particularly the United States, is projected to lead the global market. The market size can be accredited to the presence of prominent pharmaceutical companies, continuously working on producing biosimilars along with proactive regulatory authorities such as the United States FDA for maintaining the quality of the drugs.

Owing to a substantial portion of the geriatric population in the region, Europe turns out to be another key market. The older population is more susceptible to develop diseases such as arthritis, hence the government is taking multiple initiatives to promote effective treatment methods. The presence of influential academic and research institutions along with a well-structured research infrastructure also fuels market growth.

The Asia Pacific adalimumab drugs market value is poised to witness ample growth, accredited to rising improvements in the region’s healthcare infrastructure. Emerging economies such as India and South Korea are major centres of foreign investments. In addition, there is a trend of growing collaborations between private and public institutions to offer the best treatment outcomes to patients.

Adalimumab Drugs Market Report Snapshots

Adalimumab Drugs Market Size

Adalimumab Drugs Market Analysis

Adalimumab Drugs Companies

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The market is anticipated to grow at a CAGR of 5.1% during the forecast period of 2024-2032.

The market demand is driven by the increasing incidence of autoimmune diseases and the high efficacy of adalimumab drugs in treating multiple diseases.

The current market trend revolves around the increasing number of FDA approvals for marketing adalimumab biosimilars in the market. In July 2023, Cyltezo’s interchangeable adalimumab biosimilar was launched in the United States market.

Based on age groups, the market is divided into pediatrics, adult, and geriatrics.

Major distribution channels include hospitals, speciality clinics, and homecare, among others.

The route of administration can be oral and parenteral, among others.

Biologics and biosimilars are common drugs available in the market.

It includes rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, chronic plaque psoriasis, Crohn's disease, and ulcerative colitis, among others.

The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market

Key players involved in the market are F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, GlaxoSmithKline plc, Novartis AG, Pfizer Inc. (US), Biogen, Fresenius Kabi AG, Zydus Cadila, Boehringer Ingelheim International GmbH, Amgen Inc., AbbVie Inc., Abbott, CELLTRION INC. and Samsung Bioepis.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63 287899028, +63 967 048 3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124

$getforecastarray = array(); if (isset($ismapshow)) { $forecast_period_start = isset($forecast_period_start) ? $forecast_period_start : ''; if ($forecast_period_start != "") { $yearInc = 1; for ($startfrom = $forecast_period_start; $startfrom <= $forecast_period_end; $startfrom++) { $calculatFercastYear=calculateFutureValue(($getReportDetail['base_value']> 0) ? $getReportDetail['base_value'] : 100, $getReportDetail['cagr'], $yearInc); $getforecastarray[] = array('years' => "$startfrom", 'value' => $calculatFercastYear); $yearInc++; } } } $getforecastarrayJson = json_encode($getforecastarray); ?>